SynBioBeta

The future of biology is here! 🧬 Meet the founders, backers, and decision makers driving the next wave of biotech innovation at SynBioBeta 2026. 📍SynBioBeta 2026 May 4–7, 2026 • San Jose Get your pass: syntheticbiologysummit.com/?utm_source=X&…

The sight of this made me teary eyed… we miss your energy Craig Venter! A life size tribute to him is how every Synbio conference should begin this year! @SynBioBeta

What does it take to move from AI-designed molecules to real-world outcomes? Today at @SynBioBeta, @poelwijk joins discussions on programmable biomolecules and self-driving labs, exploring how advances in AI and automation are changing how new molecules are designed, tested, and optimized. The shift isn’t just in what we can design, but also about generating high quality data that improves our models and in turn determines the quality of the molecules we bring to the clinic.

In just one hour at #SynBioBeta2026, our CEO @MichaBreakstone takes the stage to outline the future of cellular engineering. Join us. We are building a future where biology is no longer destiny, but design. Thanks @SynBioBeta for the stage.

Made it to @SynBioBeta after very little sleep and this things is huge! First time, so if genetic design and unconventional computing and new approaches to bioengineering are your jazz, give us a buzz.

Day 1 @SynBioBeta first panel on building a universal anti-venom "We haven't innovated in 125yrs, since injecting horses with venom worked okay" We're now on the cusp of a universal anti-venom thanks to modern biotech

Next Generation Biotech Leaders talk begins @SynBioBeta 2026 with @EmilyLeproust CEO of @TwistBioscience .

Lee Hood @ISBLeeHood helped build the tools that made modern biology possible. Now he’s taking on the dark proteome. “The enormous revolution that will come in the next 10 years about peptide drugs will absolutely transform the entire pharmaceutical industry.” That is the prediction Leroy Hood is bringing to the #SynBioBeta Main Stage. Leroy Hood will be speaking at SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: lnkd.in/gkMTHA5e Few scientists have earned the right to call a new frontier. Hood helped develop the automated DNA sequencer that enabled the Human Genome Project. He helped build the peptide synthesizer that supported the development of the first generation of HIV protease inhibitors. He has founded or helped launch companies including Amgen @Amgen , Applied Biosystems, and now a non-profit @PhenomeHealth. He also co-founded the Institute for Systems Biology @isbsci . Now, he is turning his attention to the dark proteome. The human genome contains roughly 20,000 protein-coding genes, but the resulting proteome may contain close to a million distinct proteins once alternative splicing and post-translational modifications are taken into account. Most of those proteoforms remain invisible to the tools biology relies on today. That is the next layer Hood wants to read. At SynBioBeta, he will join @jendionne of @Stanford University and @Pumpkinseed Technologies, @susanklaeger of @genentech , and @mkoeris of @DARPA for a Main Stage session on the dark proteome and why protein sequencing may become the next frontier in biology. This is exactly why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. You can read about the dark proteome online. But the people building the tools, companies, and therapeutic platforms around it will be in San Jose. Visit the #SynBioBeta website to read the full article lnkd.in/gHJTQrvu

@ZymoChem BAYSE is a bio-based, biodegradable, microplastic-free superabsorbent polymer designed as a drop-in replacement for the petroleum-derived materials used in diapers, period pads, and incontinence products. Zymochen will be appearing at #SynBioBeta 2026, May 4-7th in San Jose, California. You can learn more about the conference and get your tickets here: lnkd.in/gkMTHA5e The company’s latest data show that BAYSE is not just more sustainable. It meets the performance bar required for industrial adoption. Against a standard petroleum-based SAP, BAYSE absorbed saline twice as fast and locked away viscous artificial menstrual fluid 3.6 times faster. In a nationwide blind in-home trial, 52% of parents preferred the BAYSE-powered diaper over their usual brand. As @harshal_ucd put it: “The hygiene industry has been waiting for a bio-based SAP that doesn’t make compromises. These results confirm that sustainability and performance are no longer in tension.” This is exactly why being in the room matters. The future of materials will not be built through passive scrolling. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. We’re excited to have ZymoChem at #SynBioBeta 2026 as they show what it looks like when biomanufacturing moves from proof of concept to commercial performance. Visit the SynBioBeta website to read the full article: lnkd.in/gr7NsVX7

“With AI transforming how sequence space is explored, the opportunity to connect synthesis directly to discovery has never been greater.” That is the future @EmilyLeproust , CEO and co-founder of @TwistBioscience, will be speaking about at #SynBioBeta 2026. Emily Leproust will be speaking at #SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… When Twist was founded in 2013, DNA synthesis was still slow, expensive, and inaccessible for many researchers. Over the past decade, Twist has helped change that with a silicon-based platform built to deliver high-quality synthetic DNA at scale. That platform has since expanded far beyond gene synthesis into NGS, target enrichment, antibody discovery, and pooled gene synthesis at scales that once would have seemed impossible. The throughline is clear: make DNA easier to build, and researchers can design, test, and iterate faster across biology, medicine, agriculture, materials, diagnostics, and more. As Emily put it, “If we can remove the technical barriers to engineering biology, we enable innovation across multiple industries at once.” That matters even more now as AI begins to explore sequence space faster than traditional wet lab workflows can validate. This is why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. At SynBioBeta, the people building the next era of DNA synthesis, AI-designed biology, and scalable bioengineering will be together in one place. Visit the #SynBioBeta website to read the full article: synbiobeta.com/read/emily-lep…

“The enzymes we design don’t exist in nature, and we deliver them in weeks.” That is how Matthew Thompson, VP of Industrial Biotech at @BiomatterD , describes the shift his team is helping bring to enzyme engineering with an AI-first platform. Matthew Thompson will be speaking at #SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: lnkd.in/gkMTHA5e For decades, enzyme programs have been constrained by long timelines, uncertain outcomes, and the limits of what nature already evolved. Too often, the most ambitious ideas never get funded because the upfront cost and risk are too high. Biomatter is working to change that with an AI-first platform for enzymes on demand. The company’s Intelligent Architecture™ platform combines generative models with physics-based engines to design enzymes from the bottom up. Instead of waiting years to discover or engineer what might work, Biomatter is building a model where companies can access working enzymes in weeks. That shift changes the economics of R&D. As Matthew puts it, “When the timeline collapses, the economics of entire programs flip.” Biomatter’s work with Kirin Holdings Co., Ltd shows what this looks like in practice. The team redesigned an enzyme for human milk oligosaccharide production and delivered it in under a month, enabling selective production of lacto-N-fucopentaose I while suppressing a key side product. This is why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. At #SynBioBeta, the people building the next generation of biomanufacturing will be sitting with the partners, investors, and technical leaders who can help turn new capabilities into real products. Visit the SynBioBeta website to read the full article: lnkd.in/gYd6eskR

For decades, researchers have learned to design around the limits of chemical DNA synthesis: difficult sequences, long timelines, failed orders, and construct sizes that forced users to fit the supplier. “The constraints they’ve been taught to accept are not laws of nature. They’re artifacts of legacy manufacturing.” That is the argument @Jason_Gammack , CEO of @AnsaBio , is making at SynBioBeta 2026. Jason Gammack will be speaking at #SynBioBeta2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… Ansa is challenging that model with a fully enzymatic DNA synthesis platform built on TdT-dNTP conjugates. In October 2025, the company launched a 50 kilobase sequence-perfect clonal DNA product, the longest synthetic DNA construct on the market, with turnaround times under 25 business days. The company is also introducing a new level of accountability with the Ansa On-Time Guarantee. If a complete order ships late, the customer pays nothing. This matters because the next generation of synthetic biology will not be limited to single genes. AI-driven design is pushing the field toward larger constructs, multi-construct systems, and libraries that legacy platforms were never built to handle. That is why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. SynBioBeta is where the people building the future of DNA synthesis, AI-driven biology, and scalable biomanufacturing come together to move the field forward. Visit the SynBioBeta website to read the full article: synbiobeta.com/read/jason-gam…

“Life is the most sophisticated manufacturing platform that has ever existed. It scales, it self-repairs, it runs on carbon and sunlight.” That is how @ola_wlodek, CEO of @BioConstructiv, frames one of the most ambitious bets in synthetic biology. Ola will be speaking at SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… Constructive Bio is building on two decades of work from Jason Chin’s lab on whole-genome writing and engineered translation. Its Syn61 strain rewrote the E. coli genome with more than 18,000 precise codon replacements, freeing three sense codons for non-canonical amino acids. The goal is not just scientific elegance. It is industrial manufacturing. Constructive Bio wants to make complex peptides and proteins in recoded organisms, including therapeutic molecules that are currently difficult, expensive, or waste-intensive to produce through conventional chemistry. The GLP-1 class is a powerful example. Drugs like semaglutide are produced by solid-phase peptide synthesis, a process associated with enormous chlorinated waste streams. Constructive’s pitch is that engineered biology can offer a cleaner, scalable, programmable alternative. This is why Ola’s perspective matters now. The company has raised $75 million to date, is advancing pharma partnerships, and is preparing a next-generation recoded strain designed for greater robustness and scalability in industrial fermentation. This is also why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. At #SynBioBeta, the people building the next generation of therapeutic manufacturing will be sitting across from the investors, partners, and builders who can help bring it to scale. Visit the SynBioBeta website to read the full article: synbiobeta.com/read/construct…

What if drug discovery didn’t start in the lab but ended there? @Latent_Labs is pushing biology into a new phase, where therapeutic molecules are designed computationally before a single experiment begins. @saakohl, CEO of Latent Labs, is speaking at #SynBioBeta2026 on May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… Their autonomous AI agent, Latent-Y, can take a natural language prompt and return lab-ready candidates, handling everything from target selection to validation. The results are already real: nanomolar binders, a 67% success rate across targets, and design cycles completed 56x faster. This is a shift from discovery to design. But the real opportunity is not just the technology. It is being in the room with the people building it. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. Join us at SynBioBeta 2026 to hear directly from Simon Kohl and see what this new paradigm looks like up close. Visit the SynBioBeta website to read the full article: synbiobeta.com/read/inside-la…